GlassScriptPhysician profile
Lakesha W High
NPI 1699143347
$2,562.61
in general payments reported to CMS, 2019-2025
23 companies · $563 in 2025
The $563 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $434 · 2023: $738 · 2024: $665 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $517.30 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $457.02 | 2022-2025 | |
| Lilly USA, LLC | $262.40 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Inspire Medical Systems, INC. | $178.33 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $174.27 | 2022-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.09 | 2023-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $125.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $102.89 | 2024-2025 | Spravato |
| Dexcom, INC. | $85.10 | 2023-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $80.71 | 2022-2024 | Shingrix, Arexvy |
| Amgen INC. | $79.78 | 2022-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $60.25 | 2021-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $45.05 | 2022 | |
| Dynavax Technologies Corporation | $41.82 | 2024-2025 | Heplisav-B |
| Pfizer INC. | $35.28 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.22 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $29.63 | 2025 | |
| Mylan Specialty L.P. | $29.40 | 2022 | |
| Exact Sciences Corporation | $21.24 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.73 | 2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $16.43 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.24 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakesha High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.